A Summary of Recent Advances in Ocular Inserts and ImplantsJervis LP*
Pharmaceutical Sciences, Fairleigh Dickinson University, Teaneck, NJ 07666, USA
- Corresponding Author:
- Lynda Paul Jervis
Fairleigh Dickinson University
1000 River Road, Teaneck, NJ, USA
Fax: 973 443-8795
E-mail: [email protected]
Received Date: November 30, 2016; Accepted Date: December 16, 2016; Published Date: January 02, 2017
Citation: Jervis LP (2017) A Summary of Recent Advances in Ocular Inserts and Implants. J Bioequiv Availab 9:320-323. doi: 10.4172/jbb.1000318
Copyright: © 2017 Jervis LP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
With the physiological and anatomical constraints put forth by the eye it is a significant challenge to the pharmaceutical scientists to target drugs to the posterior segment of the eye. Severe ocular complications such as glaucoma, uveitis, cytomegalovirus retinitis, cataracts, age related macular degeneration, diabetic retinopathy, and retinitis pigmentosa pose urgency for the treatment of ocular diseases. Hence novel drug delivery strategies and formulations are to be developed and explored to overcome and treat these posterior ocular disorders. At present the topical and intravitreal routes are widely used to deliver therapeutic entities to retinal tissue. Various controlled delivery systems, such as ocular inserts and implants are in the progress of development and may improve drug delivery drastically in the years to come. In this review, we discuss the recent developments in ocular delivery using ocular implants and inserts.